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Abstract 
The easily available diethyl ethynylphosphonate reacts with diverse aldonitrones 
under Kinugasa reaction conditions at room temperature, providing 3-phosphonylated 
β-lactams in good yields. In all cases, the reaction led to the trans-isomer exclusively. 
The trans-configuration was assigned based on 1H-NMR spectroscopy.  
 
Keywords: β-Lactams, Kinugasa reaction, aldonitrones, ethynephosphonate, 
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Introduction 
The importance of modified β-lactams is well documented. They are known not only 
as important drugs with antimicrobial activity2 but also as inhibitors of cholesterol 
absorptions3 and thrombin,4 as well as antitumor5 and anti-HIV agents.6 One of the 
important modifications comprises the substitution with phosphonyl groups, which 
are known as bioisosteric functionalities of phosphates.7,8 The phosphonyl group can 
be located either at C(3) or C(4) of the β-lactam ring.  
There are different methods known for the preparation of 4-phosphonylated β-
lactams,9–11 including the recently reported Kinugasa approach.12 In the latter case, 
the C-phosphonylated N-methyl nitrone 1 reacted with mono-substituted acetylenes 2 
yielding azetidin-2-ones 3 as mixtures of cis/trans-isomers (Scheme 1). 
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Scheme 1. Kinugasa reaction with a phosphonylated nitrone leading to 4-
phosphonylated β-lactams.12 
The synthesis of 3-phosphonylated β-lactams can be performed using different 
methods, e.g., [2+2]-cycloaddition of a phosphonylated ketene with an imine 
(Staudinger reaction),13,14 intramolecular carbene insertion into a CH-bond of a N-
benzylamide,15 and cyclization of phosphono acet-enamides.16 
The 3-phoshonylated β-lactams have never been prepared via Kinugasa reaction 
starting with diethyl ethynylphosphonate (4). On the other hand, 4 has extensively 
been used in [3+2]-cycloadditions with organic azides.17–20  
 
 
Results and Discussion 
In a recent publication we described a new approach to the synthesis of fluorinated β-
lactams via Kinugasa reaction with fluorinated nitrones and diverse monosubstituted 
acetylenes, including methyl propiolate.21 In the course of that study, preliminary 
experiments with diethyl ethynephosphonate (4) were unsuccessful and the formation 
of a complicated mixture of unidentified products was observed. For that reason, a 
series of typical nitrones 5a-h, derived from aryl or alkyl aldehydes, was prepared and 
subsequently used for the reaction with 4. The first experiment with N-benzyl-C-
phenyl nitrone (5a) and 4 was performed in anhydrous acetonitrile, in the presence of 
CuI and triethylamine (TEA), under argon atmosphere, and after three days the 
expected diethyl 1-benzyl-2-oxo-4-phenylazetidine-3-phosphonate (6a) was obtained 
as a yellowish oil in 60% yield (Scheme 2). The 1H-NMR analysis of the crude 
product revealed the presence of a single product, which was identified as the trans-
isomer on the basis of the HC(3)-HC(4) coupling constant of 2.1 Hz.22 Analogously, 
β-lactams trans-6b–g with a benzyl, phenyl or methyl group at N(1) were obtained 
with complete diastereoselectivity in good yields (Table 1). The type of substituent on 
the N-atom influence neither the reaction course nor the yield of the formed product. 
 
Scheme 2. Kinugasa reaction with diethyl ethynephosphonate (4) and nitrones 5 
Table 1. β-Lactams 6 prepared via Kinugasa reaction with diethyl 
ethynylphosphonate (4) 
Nitrone 5 R1 R2 β-lactam 6 Yield (%)a 
a Ph PhCH2 a 60 
b 4-MeOC6H4 PhCH2 b 61 
c 4-F3CC6H4 PhCH2 c 32 
d 4-BrC6H4 PhCH2 d 56 
e Furan-2-yl PhCH2 e 55 
f Ph Ph f 56 
g Ph Me g 60 
h 4-MeC6H4 Me h 62 
i Me(CH2)4 PhCH2 i 26 b 
j 
 
PhCH2 j 58 
a Yield of isolated product    b Contains ca. 5% of an unknown impurity 
 
In all reactions trans-isomers were isolated exclusively. It seems likely that 
initially formed cis-products undergo spontaneous isomerization under the basic 
reaction conditions and the thermodynamically more stable trans-isomers are formed 
as the final products. This explanation is the more likely as the H-C(3) is expected to 
show enhanced acidity resulting from the presence of the carbonyl and phosphonyl 
group. In the case of the reported 4-phosphonylated β-lactams, the formation of 
mixtures in favor of the trans-isomers was observed (up to 78:22).12 
In order to check the scope of the reaction, two nitrones derived from hexanal 
and (S)-glyceraldehyde acetonide, respectively, were included in the study of the 
reaction with 4. In the case of 5i, the trans-β-lactam 6i was isolated in rather low yield 
(Figure 1, Table 1).  
 
 
Figure 1. β-Lactams trans-6i (racemic) and (R)-trans-6j (optically active) 
 
However, again only one isomer was formed in this reaction. The reaction of the 
enantiopure 5j with 4 gave only one optically active product, trans-6j, isolated in 58% 
yield. However, the absolute configuration at C(3) and C(4) in this compound is 
unknown. 
 
 
Conclusions 
The present study shows that 3-phosphonylated β-lactams can be prepared 
conveniently using easily available diethyl ethynylphosphonate as the acetylenic 
component in the Kinugasa reaction. In contrast to the alternative method with 
phosphonylated nitrones leading to 4-phosphonylated analogues,12 the reaction 
occured with complete diastereoselectivity, and the trans-configurations were 
established in all cases based on the HC(3),HC(4) coupling constants in the 1H-NMR 
spectra.22  
 
 
Experimental Section 
General 
Melting points were determined in capillaries using a Stuart SMP30 apparatus and are 
uncorrected. IR spectra were recorded with a FT-IR NEXUS spectrophotometer as 
film or KBr pellets; absorptions in cm–1 (w = weak, m = medium, s = strong, vs = 
very strong). 1H,13C{1H}, 31P{1H} and 19F NMR spectra were measured on a Bruker 
Avance III instrument (1H at 600, 13C at 150, 31P at 234, and 19F at 565 MHz, 
respectively) in CDCl3; chemical shifts (δ) are given in ppm, coupling constants (J) in 
Hz. The multiplicity of the 13C signals was deduced using HMQC and HMBC 
techniques. 1H NMR data are presented as follows: chemical shift, multiplicity (br = 
broad, s = singlet, d = doublet, dd=doublet of doublets, t = triplet, dt = doublet of 
triplets, q = quartet, m = multiplet), coupling constant, integration. The mass spectra 
were recorded on a Finnigan MAT-95 instrument (ESI). Elemental analyses were 
performed in the Microanalytical Laboratory of the Faculty of Chemistry of the 
University of Łódź. The applied reagent diethyl ethynylphosphonate (4) was prepared 
according to a slightly modified protocol described in ref. 25; the modification 
comprises the desilylation of the final product by using commercial 
tetrabutylammonium fluoride (TBAF) solution in THF. All nitrones 5a–j were 
prepared from the corresponding aldehydes and N-hydroxyamines following the 
standard protocol.26 Copper(I) iodide was purchased from Sigma-Aldrich. Anhydrous 
acetonitrile was purchased from Acros and was degassed before use. Triethylamine 
(TEA) was purchased from Avantor; it was dried by heating over solid KOH and 
freshly distilled prior to use. 
Reaction of nitrones 5a–j with diethyl ethynylphosphonate (4) – general 
procedure 
To an oven-dried flask equipped with a septum, stirring bar and a balloon filled with 
argon was placed copper(I) iodide (190 mg, 1.0 mmol). Anhydrous and degassed 
acetonitrile (2 mL) was introduced, and to the stirred suspension (ice bath), diethyl 
ethynephosphonate (4, 162 mg, 1.0 mmol) dissolved in dry MeCN (2 mL) was added. 
After 5 min a solution of triethylamine (202 mg, 2.0 mmol) in anhydrous and 
degassed MeCN (3 mL) was added at 0 °C (ice bath) while stirring under inert 
atmosphere. After 10 min a solution of a nitrone 5a–j (1.1 mmol) in dry acetonitrile (3 
mL) was added to the suspension of the copper-acetylene complex. After another 10 
min, the ice bath was removed and the reaction mixture was left at room temperature 
for 72 h. After this time, methylene chloride (5 mL) was added and the solvents were 
removed under reduced pressure. Crude products 6 were purified by flash column 
chromatography (conditions: Grace Reveleris X2 apparatus with UV-Vis and ELSD 
detection, using commercially available 12 g or 24 g SiO2 columns, pressure 20 psi, 
solvent flow rate 25 mL/min) using petroleum ether with increasing amounts of ethyl 
acetate (up to 100% of AcOEt) as eluent. 
Diethyl trans-1-benzyl-2-oxo-4-phenylazetidine-3-phosphonate (6a): light-yellow 
oil (224 mg, 60%). IR (νmax, cm-1): 716m, 971w, 1025m, 1171w, 1260w, 1395w, 
1450w, 1759s (C=O), 2854w, 2926w, 2986w. 1H NMR (600 MHz, CDCl3): δ 1.22 
(3H, t, 3JHH 7.1 Hz, P(O)(OCH2CH3)2), 1.23 (3H, t, 3JHH 7.1 Hz, P(O)(OCH2CH3)2), 
3.41 (1H, dd, 3JHP 14.8 Hz, 3JHH 2.1 Hz, CHP(O)(OCH2CH3)2), 4.03–4.11 (4H, m, 
P(O)(OCH2CH3)2), 3.76, 4.81 (2H, AB system, 2d, 2JHH 15.2 Hz, CH2Ph), 4.55 (1H, 
dd, 2JHP 8.6 Hz, 3JHH 2.5 Hz, CHPh), 7.12–7.13 (2H, m, 2CHarom), 7.19–7.25 (5H, m, 
5CHarom), 7.26–7.31 (3H, m, 3CHarom). 13C NMR (150 MHz, CDCl3) δ 16.3, 16.4 (2C, 
2d, 3JCP(1) 2.7 Hz, 3JCP(2) 2.8 Hz, P(O)(OCH2CH3)2), 45.0 (d, 4JCP 1.9 Hz, CH2Ph), 
55.3 (d, 2JCP 2.2 Hz, CHPh), 57.1 (d, 1JCP 143.3 Hz, CHP(O)(OCH2CH3)2), 62.6, 62.7 
(2C, 2d, 2JCP(1) 6.2 Hz, 2JCP(2) 6.4 Hz, P(O)(OCH2CH3)2), 126.4, 127.8, 128.3, 128.7, 
128.9, 129.1 (10CHarom), 134.8 (1Carom), 136.3 (d, 3JCP 2.3 Hz, 1Carom), 161.4 (d, 2JCP 
6.6 Hz, C=O). 31P NMR (243 MHz, CDCl3) δ 18.60 (s, P(O)(OCH2CH3)2). MS: m/z 
(%) 396.3 (100, [M+Na]+). Anal. Calcd for C20H24NO4P (373.38): C, 64.33; H, 6.48; 
N, 3.75. Found: C, 64.30; H, 6.44; N, 3.69 %. 
Diethyl trans-1-benzyl-4-(4-methoxyphenyl)-2-oxoazetidine-3-phosphonate (6b): 
light-yellow oil (246 mg, 61%). IR (νmax, cm-1): 955m, 1032vs, 1167s, 1252vs, 1600s, 
1763vs (C=O), 2932w, 2982w. 1H NMR (600 MHz, CDCl3): δ 1.31 (3H, t, 3JHH 7.1 
Hz, P(O)(OCH2CH3)2), 1.32 (3H, t, 3JHH 7.1 Hz, P(O)(OCH2CH3)2), 3.49 (1H, dd, 
3JHP 14.7 Hz, 3JHH 2.3 Hz, CHP(O)(OCH2CH3)2), 3.80, 4.87 (2H, AB system, 2JHH 
15.2 Hz, CH2Ph), 3.83 (3H, s, OCH3), 4.12–4.23 (4H, m, P(O)(OCH2CH3)2), 4.60 
(1H, dd, 3JHP 8.5 Hz, 2JHH 2.5 Hz, CHC6H4OCH3), 7.19–7.22 (4H, m, 4CHarom), 7.38–
7.44 (1H, m, 1CHarom), 7.27–7.34 (4H, m, 4CHarom). 13C NMR (150 MHz, CDCl3): δ 
16.3, 16.4 (2C, 2d, 3JCP(1) 2.6 Hz, 3JCP(2) 2.7 Hz, P(O)(OCH2CH3)2), 44.8 (d, 4JCP 1.8 
Hz, CH2Ph), 55.3 (d, 2JCP 2.8 Hz, CHC6H4OCH3), 57.1 (d, 1JCP 142.7 Hz, 
CHP(O)(OCH2CH3)2), 62.5, 62.6 (2C, 2d, 2JCP(1) 6.2 Hz, 2JCP(2) 6.4 Hz, 
P(O)(OCH2CH3)2), 114.6 (OCH3), 127.7, 127.8, 128.3, 128.7, 128.9, 129.2, 130.6 
(9CHarom), 134.9 (brs, 1Carom), 160.1 (1Carom), 161.1 (1Carom), 162.0 (d, 2JCP 6.6 Hz, 
C=O). 31P NMR (243 MHz, CDCl3): δ 18.77 (s, P(O)(OCH2CH3)2). MS: m/z (%) 
426.3 (100, [M+Na]+). Anal. Calcd for C21H26NO5P (403.41): C, 62.52; H, 6.50; N, 
3.47. Found: C, 62.31; H, 6.33; N, 3.56 %. 
Diethyl trans-1-benzyl-2-oxo-4-[4-(trifluoromethyl)phenyl]azetidine-3-
phosphonate (6c): light-yellow oil (141 mg, 32%). IR (νmax, cm-1): 960s, 1117s, 
1170s, 1255s, 1396m, 1600s, 1760vs (C=O), 2930m, 2982m. 1H NMR (600 MHz, 
CDCl3): δ 1.24 (6H, brt, 3JHH 7.0 Hz, P(O)(OCH2CH3)2), 3.38 (1H, dd, 3JHH 14.9 Hz, 
3JHH 2.2 Hz, CHC6H4CF3), 4.01–4.13 (4H, m, P(O)(OCH2CH3)2), 3.81, 4.81 (2H, AB 
system, 2JHH 15.2 Hz, CH2Ph), 4.60 (1H, dd, 3JHP 8.7 Hz, 2JHH 2.6 Hz, 
CHP(O)(OCH2CH3)2), 7.11–7.13 (2H, m, 2CHarom), 7.20–7.25 (3H, m, 3CHarom), 
7.30–7.32 (2H, m, 2CHarom), 7.55–7.56 (2H, m, 2CHarom). 13C NMR (150 MHz, 
CDCl3): δ 16.3, 16.4 (2C, 2d, 3JCP(1) 1.8 Hz, 3JCP(2) 2.0 Hz, P(O)(OCH2CH3)2), 45.4 
(d, 4JCP 1.8 Hz, CH2Ph), 54.7 (d, 2JCP 2.0 Hz, CHC6H4CF3), 57.2 (d, 1JCP 143.9 Hz, 
CHP(O)(OCH2CH3)2), 62.8, 62.9 (2C, 2d, 2JCP(1) 6.2 Hz, 2JCP(2) 6.5 Hz, 
P(O)(OCH2CH3)2), 123.8 (q, 1JCF 270.6 Hz, CF3), 126.1 (q, 3JCF 37.2 Hz, 2 CHarom), 
128.0 (1Carom), 126.8, 128.4, 128.8 (5CHarom), 131.2 (q, 2JCF 32.6 Hz, CaromCF3), 
134.4 (1Carom), 140.7 (brs, 1Carom), 161.6 (d, 2JCP 6.5 Hz, C=O). 31P NMR (243 MHz, 
CDCl3): δ 18.60 (s, P(O)(OCH2CH3)2). 19F NMR (565 MHz, CDCl3): δ –62.78 (s, 
CF3). MS: m/z (%) 464.2 (100, [M+Na]+). Anal. Calcd for C21H26NO5P (441.38): C, 
57.14; H, 5.25; N, 3.17. Found: C, 57.30; H, 5.41; N, 3.10 %. 
Diethyl trans-1-benzyl-4-(4-bromophenyl)-2-oxoazetidine-3-phosphonate (6d): 
light-yellow oil (253 mg, 56%). IR (νmax, cm-1): 732w, 884m, 970m, 1027s, 1154m, 
1249m, 1394s, 1486m, 1765vs (C=O), 2933m, 3028w. 1H NMR (600 MHz, CDCl3): 
δ 1.22, 1.23 (6H, 2t, 3JHH(1) 7.0 Hz, 3JHH(2) 7.1 Hz, P(O)(OCH2CH3)2), 3.36 (1H, dd, 
3JHP 14.8 Hz, 3JHH 2.0 Hz, CHP(O)(OCH2CH3)2), 4.02–4.12 (4H, m, 
P(O)(OCH2CH3)2), 3.76, 4.78 (2H, AB system, 2JHH 15.2 Hz, CH2Ph), 4.50 (1H, dd, 
3JHP 8.7 Hz, 2JHH 2.6 Hz, CHC6H4OCH3), 7.05–7.06 (1H, m, 1CHarom), 7.10–7.12 
(2H, m, 2CHarom), 7.19–7.25 (4H, m, 4CHarom), 7.41–7.43 (2H, m, 2CHarom). 13C 
NMR (150 MHz, CDCl3): δ 16.3, 16.4 (2C, 2d, 3JCP(1) 2.1 Hz, 3JCP(2) 2.3 Hz, 
P(O)(OCH2CH3)2), 45.1 (d, 4JCP 1.9 Hz, CH2Ph), 54.7 (d, 2JCP 2.1 Hz, CHC6H4Br), 
57.1 (d, 1JCP 143.5 Hz, CHP(O)(OCH2CH3)2), 62.7, 62.8 (2d, 2JCP(1) 6.2 Hz, 2JCP(2) 
6.4 Hz, P(O)(OCH2CH3)2), 127.9, 128.1, 128.4, 128.8, 132.4 (9CHarom), 122.9, 134.5 
(2Carom), 135.5 (d, 3JCP 2.4 Hz, 1Carom), 161.7 (d, 2JCP 6.6 Hz, C=O). 31P NMR (243 
MHz, CDCl3): δ 18.19 (s, P(O)(OCH2CH3)2). MS: m/z (%) 474.2, 476.2 (100, 65 
[M+Na]+). Anal. Calcd for C21H26NO5P (452.28): C, 53.11; H, 5.13; N, 3.10. Found: 
C, 53.16; H, 5.38; N, 3.32 %. 
Diethyl trans-1-benzyl-4-(furan-2-yl)-2-oxoazetidine-3-phosphonate (6e): light-
yellow oil (200 mg, 55%). IR (νmax, cm-1): 701s, 745vs, 970s, 1027vs, 1268vs, 1401s, 
1774vs (C=O), 2908m, 2984s, 2985w, 3050m. 1H NMR (600 MHz, CDCl3): δ 1.33, 
1.34 (6H, 2t, 3JHH(1) 7.0 Hz, 3JHH(2) 6.9 Hz, P(O)(OCH2CH3)2), 3.87 (1H, dd, 3JHH 
11.8 Hz, 3JHP 2.6 Hz, C(4)H), 3.91, 4.74 (2H, AB system, 2JHH 5.3 Hz, CH2Ph), 4.16–
4.24 (4H, m, P(O)(OCH2CH3)2), 4.69 (1H, dd, 3JHH 6.1 Hz, 2JHP 2.6 Hz, 
CHP(O)(OCH2CH3)2), 6.31–6.32 (1H, m, 1CHarom), 6.34–6.35 (1H, m, 1CHarom), 
7.23–7.24 (2H, m, 2CHarom), 7.27–7.30 (1H, m, 1CHarom), 7.32–7.34 (2H, m, 
2CHarom), 7.40–7.41 (1H, m, 1CHarom). 13C NMR (150 MHz, CDCl3): δ 16.3, 16.4 
(2C, 2d, 3JCP(1) 3.4 Hz, 3JCP(2) 4.0 Hz, P(O)(OCH2CH3)2), 45.2 (d, 4JCP 1.5 Hz, 
CH2Ph), 48.7 (d, 2JCP 2.1 Hz, C(4)H), 53.5 (d, 1JCP 144.3 Hz, CHP(O)(OCH2CH3)2), 
62.7, 62.8 (2C, 2d, 2JCP(1) 6.2 Hz, 2JCP(2) 6.4 Hz, P(O)(OCH2CH3)2), 110.5, 110.6, 
127.7, 128.2, 128.7 (8CHarom), 143.5 (1CHarom), 134.9 (1Carom), 148.6 (d, 3JCP 2.9 Hz, 
1Carom), 161.5 (d, 2JCP 6.6 Hz, C=O). 31P NMR (243 MHz, CDCl3): δ 18.44 (s, 
P(O)(OCH2CH3)2).  MS: m/z (%) = 386.2 (100, [M+Na]+). Anal. Calcd for 
C18H22NO5P (363.34): C, 59.50; H; 6.10; N, 3.85. Found: C, 59.53; H, 6.04; N, 3.56 
%. 
Diethyl trans-2-oxo-1,4-diphenylazetidine-3-phosphonate (6f). Pale orange crystals 
(201 mg, 56%), mp 93–95 ºC (CH2Cl2/petroleum ether). IR (νmax, cm-1): 690m, 777s, 
981s, 1045s, 1149m, 1270s, 1385s, 1505s, 1600m, 1699w, 1746vs (C=O), 2849w, 
2963m, 2981m, 3063w. 1H NMR (600 MHz, CDCl3): δ 1.18–1.17 (6H, m, 
P(O)(OCH2CH3)2), 3.47 (1H, dd, 3JHP 15.5 Hz, 3JHH 2.8 Hz, CHP(O)(OCH2CH3)2), 
4.09–4.25 (4H, m, P(O)(OCH2CH3)2), 5.15 (1H, dd, 3JHP 9.2 Hz, 2JHH 2.8 Hz, CHPh), 
7.26–7.30 (5H, m, 5CHarom), 7.15–7.21 (5H, m, 5CHarom). 13C NMR (150 MHz, 
CDCl3): δ 16.4 (d, 3JCP 2.7 Hz, P(O)(OCH2CH3)2), 55.9 (d, 2JCP 2.3 Hz, CHPh), 57.3 
(d, 1JCP 143.3 Hz, CHP(O)(OCH2CH3)2), 62.8, 63.2 (2C, 2d, 2JCP(1) 6.5 Hz, 2JCP(2) 
6.2 Hz, P(O)(OCH2CH3)2), 117.0, 124.3, 125.9, 128.9, 129.1, 129.3 (10CHarom), 136.6 
(d, 3JCP 2.6 Hz, 1Carom), 137.3 (d, 4JCP 2.1 Hz, 1Carom), 159.0 (d, 2JCP 6.3 Hz, C=O). 
31P NMR (243 MHz, CDCl3): δ 17.97 (s, P(O)(OCH2CH3)2). MS: m/z (%) 382.3 (100, 
[M+Na]+). Anal. Calcd for C19H22NO4P (359.36): C, 63.50; H, 6.17; N, 3.90. Found 
C, 63.76; H, 6.10; N, 3.92 %. 
Diethyl trans-1-methyl-2-oxo-4-phenylazetidine-3-phosphonate (6g): light-yellow 
oil (178 mg, 60%). IR (νmax, cm-1): 824m, 1028m, 1052s, 1166m, 1252s, 1442m, 
1453w, 1761vs (C=O), 2927m, 2984m. 1H NMR (600 MHz, CDCl3): δ 1.33 (3H, t, 
3JHH 7.0 Hz, P(O)(OCH2CH3)2), 1.38 (3H, t, 3JHH 7.0 Hz, P(O)(OCH2CH3)2), 2.83 
(3H, brs, NCH3), 3.44 (1H, dd, 2JHP 16.5 Hz, 3JHH 1.6 Hz, CHP(O)(OCH2CH3)2), 
4.12–4.32 (4H, m, P(O)(OCH2CH3)2), 4.73 (1H, dd, 3JHP 10.9 Hz, 2JHH 2.5 Hz, 
CHPh), 7.32–7.33 (2H, m, 2CHarom), 7.36–7.39 (1H, m, 1CHarom), 7.41–7.43 (2H, m, 
2CHarom). 13C NMR (150 MHz, CDCl3): δ 16.3, 16.4 (2C, 2d, 3JCP(1) 1.9 Hz, 3JCP(2) 
1.8 Hz, P(O)(OCH2CH3)2), 27.6 (d, 4JCP 1.6 Hz, NCH3), 57.3 (d, 2JCP 2.5 Hz, CHPh), 
57.6 (d, 1JCP 143.2 Hz, CHP(O)(OCH2CH3)2), 62.5, 62.9 (2C, 2d, 2JCP(1) 6.1 Hz, 
2JCP(2) 6.5 Hz, P(O)(OCH2CH3)2), 126.2, 128.9, 129.2 (5CHarom), 136.5 (d, 3JCP 2.4 
Hz, 1Carom), 162.0 (d, 2JCP 6.2 Hz, C=O). 31P NMR (243 MHz, CDCl3): δ 18.96 (s, 
P(O)(OCH2CH3)2). MS: m/z (%) 320.2 (100, [M+Na]+). Anal. Calcd for C14H20NO4P 
(297.29): C, 56.56; H, 6.78; N, 4.71. Found: C, 56.75; H, 7.00; N, 4.43 %. 
Diethyl trans-1-methyl-4-(4-methylphenyl)-2-oxoazetidine-3-phosphonate (6h): 
light-yellow oil (193 mg, 62%). IR (νmax, cm-1): 973s, 1014m, 1049s, 1160m, 1252s, 
1388w, 1442m, 1511w, 1761vs (C=O), 2927m, 2984m. 1H NMR (600 MHz, CDCl3): 
δ 1.32 (3H, t, 3JHH 7.1 Hz, P(O)(OCH2CH3)2), 1.36 (3H, t, 3JHH 7.0 Hz, 
P(O)(OCH2CH3)2), 2.37 (s, 3H, CH3C6H4), 2.80 (3H, s, NCH3), 3.41 (1H, dd, 2JHP 
16.4 Hz, 3JHH 1.6 Hz, CHP(O)(OCH2CH3)2), 4.10–4.31 (4H, m, P(O)(OCH2CH3)2), 
4.68 (1H, dd, 3JHP 10.9 Hz, 2JHH 2.5 Hz, CHC6H4CH3), 7.19–7.22 (4H, m, 4CHarom). 
13C NMR (150 MHz, CDCl3): δ 16.3, 16.4 (2C, 2d, 3JCP(1) 1.9 Hz, 3JCP(2) 1.9 Hz, 
P(O)(OCH2CH3)2), 27.5 (d, 4JCP 1.6 Hz, NCH3), 21.1 (CH3C6H4), 54.1 (d, 2JCP 2.8 
Hz, CHC6H4CH3), 57.6 (d, 1JCP 137.5 Hz, CHP(O)(OCH2CH3)2), 62.4, 62.9 (2C, 2d, 
2JCP(1) 6.0 Hz, 2JC,P(2) 6.4 Hz, P(O)(OCH2CH3)2), 126.2, 129.8 (4CHarom), 133.4 (d, 
3JCP 2.4 Hz, 1Carom), 138.9 (1Carom), 162.0 (d, 2JCP 6.2 Hz, C=O). 31P NMR (243 
MHz, CDCl3): δ 19.11 (s, P(O)(OCH2CH3)2). MS: m/z (%) 334.3 (100, [M+Na]+). 
Anal. Calcd for C15H22NO4P (311.31): C, 57.87; H, 7.12; N, 4.50. Found: C, 57.65; 
H, 7.15; N, 4.51 %. 
Diethyl trans-1-benzyl-2-oxo-4-(pent-1-yl)azetidine-3-phosphonate (6i): pale-
yellow oil (96 mg, 26%); could not be obtained in analytically pure form (see Table 
1). IR (νmax, cm-1): 731s, 1023s, 1241s, 1404m, 1457m, 1757vs (C=O), 2927s, 3053m. 
1H NMR (600 MHz, CDCl3): δ 0.87 (3H, t, 2JHP 15.0 Hz, CH3), 1.20–1.47 (14H, m, 
P(O)(OCH2CH3)2, (CH2)4), 3.26 (1H, dd, 2JHP 15.0 Hz, 3JHH 2.3 Hz, 
CHP(O)(OCH2CH3)2), 3.69–3.73 (1H, m, CH(CH2)4), 4.12, 4.72, (2H, AB system, 
2JHH 15.5 Hz, CH2Ph), 4.16–4.24 (4H, m, P(O)(OCH2CH3)2), 7.31–7.32 (3H, m, 
3CHarom), 7.35–7.38 (2H, m, 2CHarom). 13C NMR (150 MHz, CDCl3): δ 16.4 (d, 3JCP 
6.1 Hz, P(O)(OCH2CH3)2), 32.6 (d, 3JCP 2.6 Hz, CHCH2), 44.8 (d, 4JCP 1.9 Hz, 
CH2Ph), 52.8 (d, 1JCP 145.9 Hz, CHP(O)(OCH2CH3)2), 53.2 (d, 2JCP 2.7 Hz, 
CH(CH2)4), 62.4, 62.6 (2C, 2d, 2JCP(1) 6.3 Hz, 2JCP(2) 6.5 Hz, P(O)(OCH2CH3)2), 
127.7, 128.1, 128.7 (5CHarom), 135.4 (1Carom), 161.7 (d, 2JCP 6.6 Hz, C=O). 31P NMR 
(243 MHz, CDCl3): δ 20.00 (s, P(O)(OCH2CH3)2). MS: m/z (%) 390.4 (100, 
[M+Na]+). 
Diethyl (S)-trans-1-benzyl-4-(2,2-dimethyl-1,3-dioxolan-4-yl)-2-oxoazetidine-3-
phosphonate (6j): pale-yellow oil (230 mg, 58%). [α]D22 = +36.4 (c 1.0 in DCM). IR 
(νmax, cm-1): 970m, 1028m, 1042m, 1155m, 1257m, 1381w, 1453w, 1763vs (C=O), 
2931w, 2985w. 1H NMR (600 MHz, CDCl3): δ 1.19–1.29 (6H, m, P(O)(OCH2CH3)2), 
1.25, 1.27 (6H, 2s, 2CH3), 3.20 (1H, dd, 3JHP 14.9 Hz, 3JHH 2.4 Hz, 
CHP(O)(OCH2CH3)2)), 3.58 (1H, dt, 3JHH(1) 6.6 Hz, 3JHH(2) 2.7 Hz, CHOC(CH3)2), 
3.69 (1H, dd, 2JHH(1) 8.9 Hz, 3JHH(2) 4.9 Hz, CH2OC(CH3)2), 3.93 (1H dd, 2JHH(1) 8.9 
Hz, 3JHH(2) 6.9 Hz, CH2OC(CH3)2), 4.55 (1H, dd, 3JHH 6.1 Hz, 2JHP 2.5 Hz, 
CHP(O)(OCH2CH3)2), 4.04–4.12 (5H, m, P(O)(OCH2CH3)2), CHP(O)(OCH2CH3)2), 
4.12, 4.77 (2H, AB system, 2JHH 15.2 Hz, CH2Ph), 7.20–7.21 (1H, m, 1CHarom), 7.26–
7.27 (4H, m, 4CHarom). 13C NMR (150 MHz, CDCl3): δ 16.3, 16.4 (2C, 2d, 3JCP(1) 4.2 
Hz, 3JC,P(2) 4.2 Hz, P(O)(OCH2CH3)2), 25.0, 26.5 (C(CH3)2), 45.8 (d, 4JCP 1.9 Hz, 
CH2Ph), 49.3 (d, 1JCP 147.8 Hz, CHP(O)(OCH2CH3)2), 54.3 (d, 2JCP 1.9 Hz, 
CHCHP(O)(OCH2CH3)2), 62.6, 62.7 (2C, 2d, 2JC,P(1) 6.3 Hz, 2JCP(2) 6.4 Hz, 
P(O)(OCH2CH3)2), 66.0 (CH2OC(CH3)2), 77.5 (d, 2JCP 3.5 Hz, 
CHCHP(O)(OCH2CH3)2), 110.6 (C(CH3)2), 127.7, 128.6, 128.6 (4CHarom), 135.4 
(1Carom), 161.1 (d, 2JCP 6.6 Hz, C=O). 31P NMR (243 MHz, CDCl3): δ 19.06 (s, 
P(O)(OCH2CH3)2). MS: m/z (%) = 420.3 (100, [M+Na]+). Anal. Calcd for 
C19H28NO6P (397.40): C, 57.42; H, 7.10; N, 3.52. Found: C, 57.40; H, 7.34; N, 3.33 
%. 
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